Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

-  ORA -D-013-2 is the second of two Phase 3 trials under FDA protocol -  ORA -D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK , July 26, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a